Search Results - "Gao, Yingsheng"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice by Qian, Minyi, Lyu, Qianqian, Liu, Yujie, Hu, Haiyang, Wang, Shilei, Pan, Chuyue, Duan, Xubin, Gao, Yingsheng, Qi, Lian-Wen, Liu, Weizhi, Wang, Lirui

    Published in Marine drugs (02-07-2019)
    “…Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, and there is no standard and efficient therapy for it. Chitosan oligosaccharide (COS) is widely…”
    Get full text
    Journal Article
  2. 2

    The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses by Yang, Yuanxun, Yu, Lei, Sheng, Zejuan, Lin, Hui, Weng, Zuyi, Song, Wei, Cao, Bei, Zhao, Yu, Gao, Yingsheng, Ni, Shumao, Wang, Huimin, Ma, Tingting, Huang, Lei, Sun, Caixia, Li, Juan

    Published in Frontiers in pharmacology (29-04-2024)
    “…TT-01025-CL is an oral, irreversible small molecule that potently inhibits vascular adhesion protein-1 (VAP-1) for the treatment of inflammation associated…”
    Get full text
    Journal Article
  3. 3

    Discovery of a novel orally bioavailable NLRP3 inflammasome inhibitor, TTS-X, for potential treatment of inflammatory bowel disease by Gao, Yingsheng, Li, Lin, Pan, Shan, Gao, You, Zhao, Zheng, Wu, Di, Sheng, Zejuan, Wu, Yongqian

    Published in The Journal of immunology (1950) (01-05-2023)
    “…Abstract Inappropriate activation of the NLRP3 inflammasome has been implicated in multiple inflammatory diseases, including inflammatory bowel disease…”
    Get full text
    Journal Article
  4. 4

    TP53 Mutations Promote Immunogenic Activity in Breast Cancer by Chen, Cai, Wang, Lirui, Gao, Yingsheng, Jiang, Zehang, Liu, Zhixian, Wang, Xiaosheng

    Published in Journal of oncology (01-01-2019)
    “…Background. Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast…”
    Get full text
    Journal Article
  5. 5

    Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans by Pan, Chuyue, Liu, Jun, Gao, Yingsheng, Yang, Maohui, Hu, Haiyang, Liu, Chang, Qian, Minyi, Yuan, Hai-Yang, Yang, Song, Zheng, Ming-Hua, Wang, Lirui

    Published in Cell metabolism (05-12-2023)
    “…Metabolic dysfunction-associated steatohepatitis (MASH) is a leading risk factor for liver cirrhosis and hepatocellular carcinoma. Here, we report that CHRNA4,…”
    Get more information
    Journal Article
  6. 6

    Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis by Qian, Minyi, Hu, Haiyang, Yao, Ying, Zhao, Danyang, Wang, Shilei, Pan, Chuyue, Duan, Xubin, Gao, Yingsheng, Liu, Jun, Zhang, Yufei, Yang, Song, Qi, Lian‐Wen, Wang, Lirui

    Published in Liver international (01-03-2020)
    “…Background & Aims Nonalcoholic fatty liver disease encompasses isolated steatosis or nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). NASH…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer by Khan, Ghulam Jilany, Gao, Yingsheng, Gu, Ming, Wang, Lai, Khan, Sara, Naeem, Farah, Semukunzi, Herve, Roy, Debmalya, Yuan, Shengtao, Sun, Li

    Published in Current cancer drug targets (2018)
    “…Epithelial to mesenchymal transition (EMT) is a major determinant of cancer metastasis and is closely linked with TGF-β1. Intracellular proteins, including E…”
    Get more information
    Journal Article